Israeli startup DayTwo has completed a $12 million financing round from Johnson & Johnson, the world's largest medical devices company, and Check Point Software Technologies Ltd. (Nasdaq: CHKP) cofounder Marius Nacht, who founded DayTwo and increased his investment in it. This is the Series A round for DayTwo, which has raised a total of $17 million since it was founded.
Knowledgeable sources said that Nacht took part in a Weizmann Institute of Science study, after entrepreneur Dov Moran recommended it to him. During the course of the study, Nacht discovered that he was pre-diabetic, a fact of which he had previously been unaware. Had he not been tested during the trial and changed his nutritional habits accordingly, he probably would have become a diabetic within several years.
DayTwo provides its customers with personalized nutritional recommendations through a smartphone, based on mapping and analyzing a person's intestinal microbiome, for the purpose of maintaining balanced blood sugar levels and leading a healthier life.
DayTwo's technology is based on groundbreaking research at the Weizmann Institute. The study discovered the same types of food can cause different sugar responses in the blood of different people, and that the composition of intestinal bacteria, which is unique to each person, contributes to the differing response. Among other things, the study revealed that food that causes a balanced blood sugar response in one person is liable to cause a rise in the blood sugar levels of another person. In certain cases, foods that we regard as healthy are not recommended, and vice versa.
The company recently launched a partners program that enables dieticians, nutritionists, and clinics dealing in personalized nutrition to benefit from this breakthrough technology and provide personalized service based on an analysis of their customers' intestinal bacteria.
Published by Globes [online], Israel Business News - www.globes-online.com - on June 27, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017